Under the agreement, Brookwood has exclusive rights to all pharmaceutical applications of the technology. The PharmaSol technology can be used to formulate drugs into nanostructured lipid carriers (NLCs), which offer a number of advantages over other drug delivery nanotechnologies such as liposomes, emulsions and solid lipid nanoparticles.
Brookwood is currently offering PharmaSol technology to potential customers, while also generating additional data to accelerate product development of the NLC drug delivery platform.
Arthur Tipton, president of Brookwood, said: “This license further broadens the drug delivery technology offerings of SurModics and Brookwood and complements our existing portfolio.”